One study of breast cancer implied that patients with low CBX7 had lower survival and were more likely to develop lymph node metastasis, P53 mutations, and the cancer further deteriorated, metastasized over time (Li X. et al., 2020). This evidence concerns the gene CBX7 and cancer.